NCT06654050View on ClinicalTrials.gov

Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 28, 2025

Primary Completion Date

December 1, 2027

Study Completion Date

December 31, 2027

Conditions
MesotheliomaMalignant Mesothelioma (MM)Early-stage MesotheliomaSubclinical MesotheliomaBRCA1-Associated Protein-1 (BAP1) MutationsEarly-stage BAP1-associated Malignancies
Interventions
DRUG

alrizomadlin

Alrizomadlin (APG-115) oral tablets (150 mg) taken every other day on Days 1, 3, 5, 7, 9, 11, and 13 of every cycle (1 cycle=21 days) for 8 cycles (i.e., Course 1). Individuals with stable or responding disease may receive an additional 8 cycles (i.e., Course 2). Maximum (total) of 2 treatment courses.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH